Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2002 4
2003 1
2004 2
2005 6
2006 2
2007 1
2008 2
2009 4
2010 3
2011 1
2012 8
2013 5
2014 2
2016 6
2017 9
2018 4
2019 9
2020 8
2021 8
2022 7
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier MA, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon PM, Babu S, Waters S, Deleu I, García Sáenz JA, Bria E, Cazzaniga M, Lu J, Aftimos P, Cortés J, Liu S, Tonini G, Laurent D, Habboubi N, Conlan MG, Bardia A. Bidard FC, et al. Among authors: khong h. J Clin Oncol. 2022 Oct 1;40(28):3246-3256. doi: 10.1200/JCO.22.00338. Epub 2022 May 18. J Clin Oncol. 2022. PMID: 35584336 Free PMC article. Clinical Trial.
Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction.
Liu X, Wang Y, Lu H, Li J, Yan X, Xiao M, Hao J, Alekseev A, Khong H, Chen T, Huang R, Wu J, Zhao Q, Wu Q, Xu S, Wang X, Jin W, Yu S, Wang Y, Wei L, Wang A, Zhong B, Ni L, Liu X, Nurieva R, Ye L, Tian Q, Bian XW, Dong C. Liu X, et al. Among authors: khong h. Nature. 2019 Mar;567(7749):525-529. doi: 10.1038/s41586-019-0979-8. Epub 2019 Feb 27. Nature. 2019. PMID: 30814730 Free PMC article.
Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial.
Soliman H, Hogue D, Han H, Mooney B, Costa R, Lee MC, Niell B, Williams A, Chau A, Falcon S, Soyano A, Armaghani A, Khakpour N, Weinfurtner RJ, Hoover S, Kiluk J, Laronga C, Rosa M, Khong H, Czerniecki B. Soliman H, et al. Among authors: khong h. Nat Med. 2023 Feb;29(2):450-457. doi: 10.1038/s41591-023-02210-0. Epub 2023 Feb 9. Nat Med. 2023. PMID: 36759673 Clinical Trial.
Adjuvants for peptide-based cancer vaccines.
Khong H, Overwijk WW. Khong H, et al. J Immunother Cancer. 2016 Sep 20;4:56. doi: 10.1186/s40425-016-0160-y. eCollection 2016. J Immunother Cancer. 2016. PMID: 27660710 Free PMC article. Review.
Demethylating Agents in the Treatment of Cancer.
Howell PM, Liu Z, Khong HT. Howell PM, et al. Among authors: khong ht. Pharmaceuticals (Basel). 2010 Jul 2;3(7):2022-2044. doi: 10.3390/ph3072022. Pharmaceuticals (Basel). 2010. PMID: 27713340 Free PMC article. Review.
91 results